title: Molecular biologic substaging of stage I lung cancer according to gender and histology.
abstract: BACKGROUND
  This study is designed to assess molecular biologic substaging according to gender and histology in patients with stage I non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Pathologic specimens were collected from 408 consecutive patients after complete resection for stage I NSCLC, with follow-up of at least 5 years. A panel of nine molecular markers was chosen for immunohistochemical analysis of the tumor: recessive oncogenes p53 and bcl-2, the protooncogene erbB-2, KI-67 proliferation index, retinoblastoma oncogene (Rb), epidermal growth factor receptor (EGFr), angiogenesis factor viii, sialyl-Tn antigen (STN), and CD-44. Cox proportional hazards regression analysis was used to construct a risk model for cancer-specific survival according to marker status, gender, and histologic subtype.
  
  
  RESULTS
  Among men, the only molecular marker associated with decreased cancer-specific survival is erbB-2; among women, there are four markers: p53, Rb, CD-44, and factor viii. Among patients with squamous cell carcinoma, the only molecular marker associated with decreased cancer-specific survival is erbB-2; among patients with adenocarcinoma (AC), there are three markers: p53, CD-44, and factor viii. Multivariable analysis of interactions among molecular markers, gender, and histology demonstrates two important relationships (hazard ratio): p53+/women (2.269) and CD-44+/AC (2.266).
  
  
  CONCLUSIONS
  Molecular biologic substaging of patients with stage I NSCLC demonstrates differential cancer-specific survival according to marker expression, gender, and histologic subtype.
authors.affiliation: Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. damic001@mc.duke.edu
authors.forename: T A
authors.initials: TA
authors.lastname: D'Amico
authors.forename: T A
authors.initials: TA
authors.lastname: Aloia
authors.forename: M B
authors.initials: MB
authors.lastname: Moore
authors.forename: J E
authors.initials: JE
authors.lastname: Herndon
authors.forename: K R
authors.initials: KR
authors.lastname: Brooks
authors.forename: C L
authors.initials: CL
authors.lastname: Lau
authors.forename: D H
authors.initials: DH
authors.lastname: Harpole
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D005260:Female; D005819:Genetic Markers; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008967:Molecular Biology; D009367:Neoplasm Staging; D012307:Risk Factors; D012737:Sex Factors; D015996:Survival Rate
chemical_list: D005819:Genetic Markers